IPP Bureau
USFDA grants ODD to Cevidoplenib for immune thrombocytopenia
By IPP Bureau - March 23, 2024
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
Dr. Reddy's and Pharmazz inks agreement to market Centhaquine for hypovolemic shock in India
By IPP Bureau - March 23, 2024
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Zydus receives tentative approval from USFDA for Letermovir Tablets
By IPP Bureau - March 23, 2024
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
Akums introduces Hydroxyurea oral suspension for sickle cell disease
By IPP Bureau - March 22, 2024
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
Merck invests € 300 million in new Life Science production site in South Korea
By IPP Bureau - March 21, 2024
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
IFF to sell Pharma Solutions business to Roquette for US$ 2.85 billion
By IPP Bureau - March 21, 2024
Pharma Solutions operates 10 research and development and/or production sites globally
dsm-firmenich launches food and beverages pilot plant in US
By IPP Bureau - March 21, 2024
The pilot plant is focused on scaling up beverage production and will support applications
Johnson Matthey sells Medical Device Components business for US$700 million to Montagu
By IPP Bureau - March 21, 2024
The MDC business produces components for medical device manufacturers globally with a focus on precious metal alloys and nitinol
Bristol Myers Squibb completes acquisition of Karuna Therapeutics
By IPP Bureau - March 21, 2024
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Elegen launches Enfina DNA enhancement for rapid synthesis of highly complex DNA
By IPP Bureau - March 21, 2024
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
Aurobindo Pharma receives USFDA approval for Mometasone Furoate Monohydrate nasal spray
By IPP Bureau - March 20, 2024
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
Apollo appoints Dr. Madhu Sasidhar as President & CEO, Hospitals Division
By IPP Bureau - March 20, 2024
Dr Madhu will oversee Apollo's hospital business and will focus on continuing to deliver the world's best clinical outcomes
AstraZeneca buys biopharmaceutical company Fusion
By IPP Bureau - March 20, 2024
To accelerate the development of next-generation radioconjugates to treat cancer
Lonza to buy US biologics site from Roche for US$ 1.2 billion
By IPP Bureau - March 20, 2024
Lonza plans to invest approximately CHF 500 million to upgrade the facility
